Physician profile
Mohammad N Uddin
NPI 1013052406
$2,240.73
in general payments reported to CMS, 2019-2025
27 companies · $116 in 2025
The $116 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $493 · 2020: $472 · 2021: $580 · 2022: $169 · 2023: $159 · 2024: $252 · 2025: $116.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $526.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $526.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $527.31 | 2019-2024 | Repatha, Otezla |
| Indivior INC. | $295.12 | 2019-2023 | Sublocade |
| Glaxosmithkline, LLC. | $136.38 | 2019-2024 | Trelegy Ellipta |
| Abbott Laboratories | $134.93 | 2021-2024 | Freestyle Libre 3 |
| Pfizer INC. | $121.87 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $103.00 | 2019-2024 | Farxiga |
| Abbvie INC. | $96.40 | 2022-2025 | |
| Lilly USA, LLC | $92.57 | 2019-2024 | Zepbound, Mounjaro, Jardiance |
| Biohaven Pharmaceuticals, INC. | $80.43 | 2021 | |
| Novo Nordisk INC | $79.23 | 2019-2024 | Rybelsus, Ozempic |
| Amarin Pharma, INC. | $66.39 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $64.55 | 2019-2023 | Jardiance |
| Nestle Healthcare Nutrition INC. | $55.81 | 2020-2022 | |
| Biogen, INC. | $50.35 | 2020-2021 | |
| Teva Pharmaceuticals USA, INC. | $48.60 | 2019-2020 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Orexo US, INC. | $44.29 | 2019-2023 | Zubsolv |
| Acadia Pharmaceuticals INC | $32.84 | 2023 | Nuplazid |
| Alkermes, INC. | $30.19 | 2020-2022 | |
| Novartis Pharmaceuticals Corporation | $29.80 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $26.36 | 2019-2021 | |
| Si-Bone, INC. | $21.20 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $20.13 | 2024 | |
| Phathom Pharmaceuticals, INC. | $18.14 | 2024 | Voquezna |
| Dexcom, INC. | $17.40 | 2024 | Dexcom G6 Transmitter |
| Merck Sharp & Dohme LLC | $17.39 | 2020 | |
| Astellas Pharma US INC | $16.62 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $13.43 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohammad Uddin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.